Heart Rate Reduction with Ivabradine in Patients with Acute Decompensated Systolic Heart Failure

Sargento, Luís; Satendra, M.; Longo, Susana; Lousada, Nuno; Reis, Roberto Palma dos

doi:10.1007/s40256-013-0060-1

Cited by 34 publications

(32 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They noted a significant reduction in HR after the introduction of oral ivabradine, correlated with the reduction of NT-proBNP values and NYHA class. These results suggested that the addition of oral ivabradine before in that population-might be safe and efficient [18].…”

Section: Acute Decompensated Systolic Heart Failurementioning

confidence: 78%

Is There a Role for Ivabradine Beyond its Conventional Use?

Bonadei

Vizzardi

Sciatti

et al. 2014

Cardiovascular Therapeutics

View full text Add to dashboard Cite

show abstract

Section: Acute Decompensated Systolic Heart Failurementioning

confidence: 78%

Is There a Role for Ivabradine Beyond its Conventional Use?

Bonadei

Vizzardi

Sciatti

et al. 2014

Cardiovascular Therapeutics

View full text Add to dashboard Cite

show abstract

“…Sargento et al [5 ]shared their experience in 10 consecutive patients with acute HF and severely depressed LVEF who were administered ivabradine for HR control, also proving it to be effective and safe. The largest experience reported in the literature focuses on controlling catecholamine-induced tachycardia.…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, beta-blockers should not be initiated until patient stabilization in any patients who present with congestive signs and symptoms [3], so ivabradine may be useful in these situations. Ivabradine is a safe and well-tolerated drug in acute HF [4,5,6], so it seems to be an attractive option to avoid excessive tachycardization.…”

Section: Introductionmentioning

confidence: 99%

Clinical Experience with Ivabradine in Acute Heart Failure

Izco

Salinas

Fernández³

et al. 2016

Cardiology

View full text Add to dashboard Cite

Objective: Ivabradine has been shown to improve symptoms and to reduce rehospitalization and mortality in patients with severe chronic heart failure (HF). Its indication in acute HF is not clear. Acute HF patients could also benefit from HR reduction, as myocardial consumption and oxidative stress are related to tachycardia. Moreover, beta-blockers are contraindicated in cardiogenic shock and should not be initiated with congestive signs. Accordingly, we evaluated the role of ivabradine in acute HF patients. Methods: This was a retrospective analysis of 29 consecutive patients treated for acute HF in the Cardiac ICU, and for whom ivabradine was initiated during hospitalization between January 2011 and January 2014. All patients were in sinus rhythm and had a heart rate (HR) >70 bpm. Catecholamine use was necessary in 16 patients (57.1%) during the hospitalization, in 14 (87.5%) of these before ivabradine treatment. Results: Systolic blood pressure showed no variation during the first 24 h of ivabradine administration or at discharge. HR showed an absolute reduction of 10 bpm at 6 h (p < 0.001), 11 bpm at 24 h (p = 0.004) and 19 bpm (p < 0.001) at discharge. No episodes of significant bradycardia or hypotension were recorded after starting the drug. Conclusions: HR reduction with ivabradine in acute HF is well tolerated. It represents an attractive option, especially when there is excessive catecholamine-related tachycardia; this should be appropriately evaluated in randomized trials.

show abstract

“…In SHIFT, the drug was not studied in patients with acute decompensated heart failure and thus is not indicated for such patients, through recent data [17,18] suggest that beginning the drug early during a hospitalization for acute decompensated heart failure is acceptably safe and is effective in lowering heart rate. The drug also is contraindicated in patients with blood pressure less than 90/50 mmHg, and in the presence of sick sinus syndrome, sinoatrial block, or third degree AV block, unless a functioning demand pacemaker is present, and in patients with severe hepatic impairment or concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors or enhancers (ivabradine is metabolized in the liver by the P450 CYP 3A4 system).…”

Section: Ivabradinementioning

confidence: 99%

Role of New Therapies in Reducing Mortality and Major Morbidity in Patients with Systolic Heart Failure

Yurevich¹,

Borer²

2017

The Role of the Clinical Cardiac Electrophysiologist in the Management of Congestive Heart Failure

View full text Add to dashboard Cite

Though heart failure therapies, particularly for systolic heart failure, have developed rapidly and markedly during the past four decades, a need for additional relief persists and is progressively being met. Two new drugs have been approved for marketing in the United States within the past two years, and two other glucose lowering therapies for diabetes appear to have efficacy for heart failure as well. In addition, device therapy for heart failure has progressed markedly during the past 5 years, particularly in refinements of the indications and applications of devices to minimize symptoms and hospitalizations and to maximize survival. This chapter will outline these recent developments.

show abstract

Heart Rate Reduction with Ivabradine in Patients with Acute Decompensated Systolic Heart Failure

Abstract: In the present cohort of patients with ADSHF and HR >70 bpm, the selective reduction of HR with oral ivabradine was safe and efficient.

Cited by 34 publications

References 27 publications

Is There a Role for Ivabradine Beyond its Conventional Use?

Is There a Role for Ivabradine Beyond its Conventional Use?

Clinical Experience with Ivabradine in Acute Heart Failure

Role of New Therapies in Reducing Mortality and Major Morbidity in Patients with Systolic Heart Failure

Contact Info

Product

Resources

About